DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Monoclonal Antibodies Market 2020-2030 by Source, Category, Production Type, Application, End User, and Country: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com’s offering.
The Asia Pacific monoclonal antibodies market is forecast to grow by 12.8% annually with a total addressable market cap of $414 billion over 2021-2030 owing to the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies.
The report is based on comprehensive research of the entire Asia Pacific monoclonal antibodies market and all its sub-segments. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 to 2030.
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter’s Fiver Forces
Based on Source, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
- Human
- Humanized
- Chimeric
- Murine
Based on Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
- Branded mAbs
- Biosimilar mAbs
Based on Production Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
- In Vitro Production
- In Vivo Production
Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
- Cancer
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Ovarian Cancer
- Other Cancer Types
- Autoimmune Diseases
- Inflammatory Diseases
- Infectious Diseases
- Other Applications
By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
- Hospitals
- Research Institutes
- Other End Users
Geographically, the following national/local markets are fully investigated:
- Japan
- China
- South Korea
- Australia
- India
- Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Source, Application, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Company Profiles
- Abbott Laboratories
- Abbvie, Inc.
- Amgen Inc.
- Astrazeneca plc
- Bayer Ag
- Bristol-Myers Squibb Company
- Eli Lilly
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co. Inc.
- Mylan N.V
- Norvatis Ag
- Pfizer
- Sanofi S.A.
For more information about this report visit https://www.researchandmarkets.com/r/wmz49v
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.